Key result
Genetic testing in unexplained LVH yields pathogenic sarcomere mutations in ~30-50% of patients.
Why the study?
The role of genetic findings in predicting development of disease, outcomes, and guiding management in HCM is evolving with larger data sets, highlighting emerging themes in genetic testing and familial evaluation.
Genetic testing in HCM is increasingly important for definitive diagnosis, risk stratification for sudden death, and guiding management strategies including the use of myosin inhibitors and future gene therapies.
Answers are grounded in this paper and cite their sources.
Supports genetic evaluation in unexplained LVH; leaves open standardization of panels and outcome impact.
Hypertrophic cardiomyopathy (HCM), defined clinically by the presence of unexplained left ventricular hypertrophy (LVH), with wall thickness ≥ 1.5 cm, is a phenotype in search of a diagnosis, which is most often a genetically determined, cardiac exclusive, or systemic disorder. Familial evaluation and genetic testing are required for definitive diagnosis. The role of genetic findings in predicting development of disease, outcomes, and increasingly to guide management is evolving with access to larger data sets. The specific mutation and sex of the patient are important determinants that ultimately are likely to guide management. The genetic/familial evaluation is influenced by the accuracy of the clinical diagnosis and the extent/expertise of the genetic laboratory. Genetic testing in a patient with unexplained LVH without systemic manifestations will yield a definite/likely pathogenetic mutation in a sarcomere (30%-50%), regulatory/functional (10%-15%) or metabolic/syndromic (< 5%) gene associated with Mendelian inheritance. The importance of oligo- and polygenic determinants, usually in the absence of Mendelian inheritance, is under investigation with important implications, particularly related to familial evaluation and definition of risk of disease development in relatives of probands. The results of genetic testing are increasingly important in management strategies related to the use of the implantable cardioverter defibrillator for prevention of sudden death, use of myosin inhibitors for refractory symptoms in patients with and without outflow tract obstruction, and-on the immediate horizon-gene therapy. This review will focus on genetic and outcome data in sarcomeric HCM, and minor causative genes with robust evidence of their association will also be considered.
No takes yet. Share an insight, caveat, or question.
García-Hernández et al. (2024) conducted a review in Hypertrophic cardiomyopathy (HCM). Genetic testing was evaluated. Genetic testing in patients with unexplained left ventricular hypertrophy yields a definite or likely pathogenetic mutation in a sarcomere, regulatory, or metabolic gene.
Synapse has enriched 10 related papers. Consider them for comparative context: